Acadia Pharmaceuticals Inc. (ACAD) Posts Phase 2 ADP Topline: Primary p=0.0603, Secondary p=0.0077
Acadia reported Phase 2 topline for remlifanserin in Alzheimer’s disease psychosis: 60 mg showed SAPS-H+D effect size 0.26 (p=0.0603) and CGI-S-ADP effect size 0.37 (p=0.0077, nominal). Safety similar to placebo. Phase 3 continues with 30 mg arm removed.Material DetailsContext by AI AnalystThis is…